Impairment of GH responsiveness to combined GH-releasing hormone and arginine administration in adult patients with Prader-Willi syndrome

Research output: Contribution to journalArticle

Abstract

Objective: It is unclear if poor health outcomes of adult patients with Prader-Willi syndrome (PWS) are influenced by GH deficiency (GHD). Few studies have been focused on PWS adults, but further information on the concomitant role of obesity on GH/IGF-I axis function is needed. The aim of our study was to investigate the prevalence of GHD in a large group of adult subjects with genetically confirmed PWS. Design and subjects: We studied the GH response to a combined administration of GHRH (1 μg/kg i.v. at 0 minutes) and arginine (ARG) (30 g i.v., infused from 0 to 30 minutes) as well as the baseline IGF-I levels, in a group of 44 PWS adults (18 males, 26 females) aged 18-41·1 years. The same protocol was carried out in a control group of 17 obese subjects (7 males, 10 females) aged 21·8-45·8 years. Measurements: Blood samples were taken at -15 and 0 minutes and then 30, 45, 60, 90 and 120 minutes after GHRH administration. Serum GH and total IGF-I concentrations were measured by chemioluminescence. Statistical analysis was performed by Student's t-test for unpaired data, and using analysis of variance for parametric and nonparametric (Mann-Whitney test) data, where appropriate. The relationship between pairs of variables was assessed by Pearson's correlation. Independent variables influencing GH secretion were tested by multiple linear regression analysis. Results: The GH response to GHRH + ARG was significantly lower in PWS patients (GH peak (mean ± SE) 8·4 ± 1·2 μg/l; AUC: 471·4 ± 77·8 μg/l/h) than obese subjects (GH peak 15·7 ± 2·9 μg/l, P <0·02; AUC 956 ± 182·9 μg/l/h, P <0·005). When considered individually, 17 of 44 PWS individuals (38·6%) were severely GHD, according to the cut-off limit of 4·1 μg/l for obese individuals, and low IGF-I-values were present in 33 PWS patients. Moreover, impaired GH response was combined with subnormal IGF-I levels in all PWS patients with GHD. Conclusions: Adult subjects with PWS had a reduced responsiveness to GHRH + ARG administration associated with reduced IGF-I levels. In addition, a severe GHD for age was demonstrated in a significant percentage of PWS subjects. These findings are in agreement with the hypothesis that a complex derangement of hypothalamus-pituitary axis occurred in PWS, and suggested that impaired GH secretion is not an artefact of obesity.

Original languageEnglish
Pages (from-to)492-499
Number of pages8
JournalClinical Endocrinology
Volume65
Issue number4
DOIs
Publication statusPublished - Oct 2006

Fingerprint

Prader-Willi Syndrome
Arginine
Hormones
Insulin-Like Growth Factor I
Area Under Curve
Obesity
Artifacts
Hypothalamus
Linear Models
Analysis of Variance
Regression Analysis

ASJC Scopus subject areas

  • Endocrinology

Cite this

@article{2538bb1adb4e4658997a4cf75f66ed43,
title = "Impairment of GH responsiveness to combined GH-releasing hormone and arginine administration in adult patients with Prader-Willi syndrome",
abstract = "Objective: It is unclear if poor health outcomes of adult patients with Prader-Willi syndrome (PWS) are influenced by GH deficiency (GHD). Few studies have been focused on PWS adults, but further information on the concomitant role of obesity on GH/IGF-I axis function is needed. The aim of our study was to investigate the prevalence of GHD in a large group of adult subjects with genetically confirmed PWS. Design and subjects: We studied the GH response to a combined administration of GHRH (1 μg/kg i.v. at 0 minutes) and arginine (ARG) (30 g i.v., infused from 0 to 30 minutes) as well as the baseline IGF-I levels, in a group of 44 PWS adults (18 males, 26 females) aged 18-41·1 years. The same protocol was carried out in a control group of 17 obese subjects (7 males, 10 females) aged 21·8-45·8 years. Measurements: Blood samples were taken at -15 and 0 minutes and then 30, 45, 60, 90 and 120 minutes after GHRH administration. Serum GH and total IGF-I concentrations were measured by chemioluminescence. Statistical analysis was performed by Student's t-test for unpaired data, and using analysis of variance for parametric and nonparametric (Mann-Whitney test) data, where appropriate. The relationship between pairs of variables was assessed by Pearson's correlation. Independent variables influencing GH secretion were tested by multiple linear regression analysis. Results: The GH response to GHRH + ARG was significantly lower in PWS patients (GH peak (mean ± SE) 8·4 ± 1·2 μg/l; AUC: 471·4 ± 77·8 μg/l/h) than obese subjects (GH peak 15·7 ± 2·9 μg/l, P <0·02; AUC 956 ± 182·9 μg/l/h, P <0·005). When considered individually, 17 of 44 PWS individuals (38·6{\%}) were severely GHD, according to the cut-off limit of 4·1 μg/l for obese individuals, and low IGF-I-values were present in 33 PWS patients. Moreover, impaired GH response was combined with subnormal IGF-I levels in all PWS patients with GHD. Conclusions: Adult subjects with PWS had a reduced responsiveness to GHRH + ARG administration associated with reduced IGF-I levels. In addition, a severe GHD for age was demonstrated in a significant percentage of PWS subjects. These findings are in agreement with the hypothesis that a complex derangement of hypothalamus-pituitary axis occurred in PWS, and suggested that impaired GH secretion is not an artefact of obesity.",
author = "G. Grugni and P. Marzullo and L. Ragusa and A. Sartorio and G. Trifir{\`o} and A. Liuzzi and A. Crin{\`o}",
year = "2006",
month = "10",
doi = "10.1111/j.1365-2265.2006.02621.x",
language = "English",
volume = "65",
pages = "492--499",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Impairment of GH responsiveness to combined GH-releasing hormone and arginine administration in adult patients with Prader-Willi syndrome

AU - Grugni, G.

AU - Marzullo, P.

AU - Ragusa, L.

AU - Sartorio, A.

AU - Trifirò, G.

AU - Liuzzi, A.

AU - Crinò, A.

PY - 2006/10

Y1 - 2006/10

N2 - Objective: It is unclear if poor health outcomes of adult patients with Prader-Willi syndrome (PWS) are influenced by GH deficiency (GHD). Few studies have been focused on PWS adults, but further information on the concomitant role of obesity on GH/IGF-I axis function is needed. The aim of our study was to investigate the prevalence of GHD in a large group of adult subjects with genetically confirmed PWS. Design and subjects: We studied the GH response to a combined administration of GHRH (1 μg/kg i.v. at 0 minutes) and arginine (ARG) (30 g i.v., infused from 0 to 30 minutes) as well as the baseline IGF-I levels, in a group of 44 PWS adults (18 males, 26 females) aged 18-41·1 years. The same protocol was carried out in a control group of 17 obese subjects (7 males, 10 females) aged 21·8-45·8 years. Measurements: Blood samples were taken at -15 and 0 minutes and then 30, 45, 60, 90 and 120 minutes after GHRH administration. Serum GH and total IGF-I concentrations were measured by chemioluminescence. Statistical analysis was performed by Student's t-test for unpaired data, and using analysis of variance for parametric and nonparametric (Mann-Whitney test) data, where appropriate. The relationship between pairs of variables was assessed by Pearson's correlation. Independent variables influencing GH secretion were tested by multiple linear regression analysis. Results: The GH response to GHRH + ARG was significantly lower in PWS patients (GH peak (mean ± SE) 8·4 ± 1·2 μg/l; AUC: 471·4 ± 77·8 μg/l/h) than obese subjects (GH peak 15·7 ± 2·9 μg/l, P <0·02; AUC 956 ± 182·9 μg/l/h, P <0·005). When considered individually, 17 of 44 PWS individuals (38·6%) were severely GHD, according to the cut-off limit of 4·1 μg/l for obese individuals, and low IGF-I-values were present in 33 PWS patients. Moreover, impaired GH response was combined with subnormal IGF-I levels in all PWS patients with GHD. Conclusions: Adult subjects with PWS had a reduced responsiveness to GHRH + ARG administration associated with reduced IGF-I levels. In addition, a severe GHD for age was demonstrated in a significant percentage of PWS subjects. These findings are in agreement with the hypothesis that a complex derangement of hypothalamus-pituitary axis occurred in PWS, and suggested that impaired GH secretion is not an artefact of obesity.

AB - Objective: It is unclear if poor health outcomes of adult patients with Prader-Willi syndrome (PWS) are influenced by GH deficiency (GHD). Few studies have been focused on PWS adults, but further information on the concomitant role of obesity on GH/IGF-I axis function is needed. The aim of our study was to investigate the prevalence of GHD in a large group of adult subjects with genetically confirmed PWS. Design and subjects: We studied the GH response to a combined administration of GHRH (1 μg/kg i.v. at 0 minutes) and arginine (ARG) (30 g i.v., infused from 0 to 30 minutes) as well as the baseline IGF-I levels, in a group of 44 PWS adults (18 males, 26 females) aged 18-41·1 years. The same protocol was carried out in a control group of 17 obese subjects (7 males, 10 females) aged 21·8-45·8 years. Measurements: Blood samples were taken at -15 and 0 minutes and then 30, 45, 60, 90 and 120 minutes after GHRH administration. Serum GH and total IGF-I concentrations were measured by chemioluminescence. Statistical analysis was performed by Student's t-test for unpaired data, and using analysis of variance for parametric and nonparametric (Mann-Whitney test) data, where appropriate. The relationship between pairs of variables was assessed by Pearson's correlation. Independent variables influencing GH secretion were tested by multiple linear regression analysis. Results: The GH response to GHRH + ARG was significantly lower in PWS patients (GH peak (mean ± SE) 8·4 ± 1·2 μg/l; AUC: 471·4 ± 77·8 μg/l/h) than obese subjects (GH peak 15·7 ± 2·9 μg/l, P <0·02; AUC 956 ± 182·9 μg/l/h, P <0·005). When considered individually, 17 of 44 PWS individuals (38·6%) were severely GHD, according to the cut-off limit of 4·1 μg/l for obese individuals, and low IGF-I-values were present in 33 PWS patients. Moreover, impaired GH response was combined with subnormal IGF-I levels in all PWS patients with GHD. Conclusions: Adult subjects with PWS had a reduced responsiveness to GHRH + ARG administration associated with reduced IGF-I levels. In addition, a severe GHD for age was demonstrated in a significant percentage of PWS subjects. These findings are in agreement with the hypothesis that a complex derangement of hypothalamus-pituitary axis occurred in PWS, and suggested that impaired GH secretion is not an artefact of obesity.

UR - http://www.scopus.com/inward/record.url?scp=33748805758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748805758&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2265.2006.02621.x

DO - 10.1111/j.1365-2265.2006.02621.x

M3 - Article

C2 - 16984242

AN - SCOPUS:33748805758

VL - 65

SP - 492

EP - 499

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 4

ER -